NP / PA
Fleming Medical Center LLC
Fleming Medical Center LLC was paid $18.63M by Medicaid between Jan 2018 and Dec 2024, across 124 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoFLEMING MEDICAL CENTER LLC
FLEMINGSBURG, KY 41041
FLEMINGSBURG, KY 41041
33aNPI1881726347assigned 03/11/2007
33bProvider typeCertified Registered Nurse Anesthetist
28Total paid$18.63M
24GClaims295,602
24DCodes billed124
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Certified Registered Nurse Anesthetist providers in Kentucky
Rank by total paid#2 of 53
Median peer was paid$84K
This provider vs. median223×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,871 | $2.04M | |
| 2019 | 44,467 | $2.10M | |
| 2020 | 44,509 | $3.53M | |
| 2021 | 47,085 | $3.54M | |
| 2022 | 44,841 | $2.48M | |
| 2023 | 40,215 | $2.62M | |
| 2024incomplete | 30,614 | $2.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 11,329 | 9,220 | $3.72M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 11,202 | 9,378 | $2.21M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.8% | 4,632 | 2,975 | $1.83M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.2% | 1,697 | 1,336 | $1.72M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.4% | 15,558 | 3,112 | $1.38M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.0% | 772 | 592 | $740K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 1,930 | 1,409 | $666K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.7% | 5,738 | 1,729 | $496K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 4,526 | 3,396 | $457K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.0% | 5,883 | 1,951 | $372K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 11,599 | 3,317 | $336K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 3,377 | 1,661 | $329K |
112 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 2,778 | $312K |
| 80053 | Comprehensive metabolic panel | 1.6% | 26,194 | $292K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 4,455 | $263K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 4,107 | $237K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.2% | 1,620 | $220K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,281 | $173K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,102 | $169K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,174 | $165K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,491 | $150K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,873 | $149K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,430 | $127K |
| G0378 | Hospital observation service, per hour | <1% | 196 | $104K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,610 | $97K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,865 | $95K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,258 | $90K |
| 84484 | <1% | 3,821 | $74K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,689 | $74K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 955 | $69K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 4,269 | $68K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,855 | $64K |
| 80061 | Lipid panel | <1% | 3,888 | $62K |
| 73630 | <1% | 881 | $60K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 313 | $60K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,911 | $56K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,790 | $54K |
| 87070 | <1% | 4,228 | $52K | |
| 73564 | <1% | 346 | $51K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,736 | $50K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,389 | $50K |
| 83605 | <1% | 3,622 | $43K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,861 | $43K |
| 85730 | <1% | 2,692 | $37K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,247 | $37K |
| 81001 | <1% | 7,530 | $35K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 612 | $34K |
| 83880 | <1% | 1,085 | $33K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,100 | $32K |
| 73610 | <1% | 426 | $32K | |
| 97161 | <1% | 536 | $32K | |
| 83735 | <1% | 4,462 | $25K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 347 | $25K |
| 83690 | <1% | 3,934 | $24K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,064 | $24K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 31 | $24K |
| 81025 | <1% | 2,290 | $24K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,707 | $21K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 72 | $20K |
| 87040 | <1% | 1,091 | $20K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,121 | $19K |
| 85610 | <1% | 4,933 | $19K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,392 | $17K |
| 82607 | <1% | 1,342 | $13K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,316 | $13K |
| 84439 | <1% | 1,642 | $13K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $13K |
| 87077 | <1% | 1,700 | $13K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $11K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 589 | $11K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 632 | $11K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 51 | $9K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 42 | $9K |
| 73030 | <1% | 114 | $8K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 33 | $8K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 175 | $7K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 22 | $7K |
| 85379 | <1% | 673 | $7K | |
| 87807 | <1% | 501 | $7K | |
| 97162 | <1% | 79 | $7K | |
| 76536 | <1% | 46 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 695 | $6K |
| 72100 | <1% | 43 | $6K | |
| 73130 | <1% | 118 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 80 | $6K |
| 82962 | <1% | 1,121 | $6K | |
| 82746 | <1% | 407 | $5K | |
| 87186 | <1% | 616 | $5K | |
| 76642 | <1% | 62 | $5K | |
| 86140 | <1% | 663 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 64 | $4K |
| 82728 | <1% | 370 | $4K | |
| 83540 | <1% | 621 | $3K | |
| 73110 | <1% | 45 | $3K | |
| 83550 | <1% | 453 | $3K | |
| 83921 | <1% | 102 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 504 | $2K |
| 96376 | <1% | 82 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 21 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,859 | $2K |
| 84703 | <1% | 193 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 622 | $1K |
| 90715 | <1% | 40 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,429 | $1K |
| 12001 | <1% | 15 | $1K | |
| 96367 | <1% | 35 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 44 | $694.05 |
| 82803 | <1% | 39 | $663.28 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,213 | $651.27 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 50 | $558.44 |
| 94760 | <1% | 47 | $487.43 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 592 | $453.55 |
| 82150 | <1% | 62 | $437.18 | |
| 85045 | <1% | 61 | $396.57 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 458 | $374.45 |
| 82565 | <1% | 15 | $213.61 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 229 | $195.99 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 423 | $178.77 |
| 85652 | <1% | 31 | $154.41 | |
| 87205 | <1% | 29 | $140.15 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 103 | $125.70 |
| 81003 | <1% | 24 | $60.40 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 14 | $6.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Parent organizationLIFEPOINT HEALTH INC
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.